Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
复制标题
DOI：
10.1128/aac.00770-18
复制
发表时间：
2018-10-01
影响因子：
4.9
通讯作者：
Horsburgh, C. Robert, Jr.
中科院分区：
文献类型：
--
作者：
Peloquin, Charles A.;Phillips, Patrick P. J.;Horsburgh, C. Robert, Jr.
秘鲁和南非的耐多药结核病患者被随机分配至11、14、17或20 mg/kg/天（最低750 mg）左氧氟沙星联合其他二线药物的体重分组标称剂量组。共有101例患者纳入非房室药代动力学分析。0 - 24 h浓度-时间曲线下面积（AUC（0-24））的中位数分别为109.49、97.86、145.33和207.04 μ g。h/ml。中位最大血浆浓度（C-max）分别为11.90、12.02、14.86和19.17 μ g/ml。更高的左氧氟沙星剂量，高达1,500毫克，每天，导致更高的暴露。(This研究已在ClinicalTrials.gov上注册，标识符为NCT 01918397。）
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharma-cokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC(0-24)) were 109.49, 97.86, 145.33, and 207.04 mu g . h/ml. Median maximum plasma concentration (C-max) were 11.90, 12.02, 14.86, and 19.17 mu g/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.)